Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours

Molecular and Cellular Endocrinology

Volumn 392, Issue 1-2, 2014, Pages 8-13

  Sponziello, Marialuisa ^a   Durante, Cosimo ^a   Boichard, Amelie ^b   Dima, Mariavittoria ^a   Puppin, Cinzia ^c   Verrienti, Antonella ^a   Tamburrano, Giulia ^a   Di Rocco, Giorgio ^a   Redler, Adriano ^a   Lacroix, Ludovic ^b   Bidart, Jean Michel ^b   Schlumberger, Martin ^b   Damante, Giuseppe ^c   Russo, Diego ^d   Filetti, Sebastiano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF UDINE   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Epigenetics; Histone methylation; Medullary thyroid cancer; RAS; RET

Indexed keywords

MESSENGER RNA; PROTEIN RET; RAS PROTEIN; TRANSCRIPTION FACTOR EZH2; EZH2 PROTEIN, HUMAN; HISTONE LYSINE METHYLTRANSFERASE; POLYCOMB REPRESSIVE COMPLEX 2; SMYD3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CHILD; COHORT ANALYSIS; DISEASE ACTIVITY; DISTANT METASTASIS; EPIGENETICS; EZH2 GENE; FAMILIAL CANCER; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC REGULATION; GENOTYPE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDULLARY THYROID CANCER; ONCOGENE RAS; PHENOTYPE; PRIORITY JOURNAL; RET GENE; REVERSE TRANSCRIPTION; RNA ISOLATION; SMYD3 GENE; SOMATIC MUTATION; THYROID CANCER; TRANSCRIPTION REGULATION; ADOLESCENT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; THYROID TUMOR; TREATMENT OUTCOME; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; POLYCOMB REPRESSIVE COMPLEX 2; THYROID NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901292802     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.04.016     Document Type: Article

References (24)

1. Ameur N., Lacroix L., Motte N., Baudin E., Caillou B., Ducreux M., Elias D., Chanson P., Schlumberger M., Bidart J.M. Mutational status of EGFR, BRAF, PI3KCA and JAK2 genes in endocrine tumors. Int. J. Cancer 2009, 124:751-753.
2. Ameur N., Lacroix L., Roucan S., Roux V., Broutin S., Talbot M., Dupuy C., Caillou B., Schlumberger M., Bidart J.M. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways. Endocr. Relat. Cancer 2009, 16:1261-1272.
3. Bae W.K., Hennighausen L. Canonical and non-canonical roles of the histone methyltransferase EZH2 in mammary development and cancer. Mol. Cell. Endocrinol. 2013, doi: 10.1016/j.mce.2013.05.002.
4. Boichard A., Croux L., Al Ghuzlan A., Broutin S., Dupuy C., Leboulleux S., Schlumberger M., Bidart J.M., Lacroix L. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J. Clin. Endocrinol. Metab. 2012, 97:E2031-E2035.
5. Borbone E., Troncone G., Ferraro A., Jasencakova Z., Stojic L., Esposito F., Hornig N., Fusco A., Orlando V. Enhancer of Zeste Homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. J. Clin. Endocrinol. Metab. 2011, 96:1029-1038.
6. Chang C.J., Hung M.C. The role of EZH2 in tumour progression. Br. J. Cancer 2012, 106:243-247.
7. Cheng A.S., Lau S.S., Chen Y., Kondo Y., Li M.S., Feng H., Ching A.K., Cheung K.F., Wong H.K., Tong J.H., Jin H., Choy K.W., Yu J., To K.F., Wong N., Huang T.H., Sung J.J. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res. 2011, 71:4028-4039.
8. Castellone M.D., Verrienti A., Rao D.M., Sponziello M., Fabbro D., Muthu M., Durante C., Maranghi M., Damante G., Pizzolitto S., Costante G., Russo D., Santoro M., Filetti S. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with pheochromocytoma and medullary thyroid carcinoma: Functional characterization. Clin. Endocrinol. (Oxford) 2010, 73:529-534.
9. Cock-Rada A.M., Medjkane S., Janski N., Yousfi N., Perichon M., Chaussepied M., Chluba J., Langsley G., Weitzman J.B. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. Cancer Res. 2012, 72:810-820.
10. Dowson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
11. Durante C., Russo D., Verrienti A., Filetti S. XL184 (cabozantinib) for medullary thyroid carcinoma. Expert Opin. Investig. Drugs 2011, 20:407-413.
12. Durante C., Paciaroni A., Plasmati K., Trulli F., Filetti S. Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma. Endocrine 2013, 44:334-342.
13. Elisei R., Cosci B., Romei C., Bottici V., Renzini G., Molinaro E., Agate L., Vivaldi A., Faviana P., Basolo F., Miccoli P., Berti P., Pacini F., Pinchera A. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J. Clin. Endocrinol. Metab. 2008, 93:682-687.
14. Hamamoto R., Silva F.P., Tsuge M., Nishidate T., Katagiri T., Nakamura Y., Furukawa Y. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006, 97:113-118.
15. Kloos R.T., Eng C., Evans D.B., Francis G.L., Gagel R.F., Gharib H., Moley J.F., Pacini F., Ringel M.D., Schlumberger M., Wells S.A. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009, 19:565-612.
16. Lombardo F., Baudin E., Chiefari E., Arturi F., Bardet S., Caillou B., Conte C., Dallapiccola B., Giuffrida D., Bidart J.M., Schlumberger M., Filetti S. Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804. J. Clin. Endocrinol. Metab. 2002, 87:1674-1680.
17. Min J., Zaslavsky A., Fedele G., McLaughlin S.K., Reczek E.E., De Raedt T., Guney I., Strochlic D.E., Macconaill L.E., Beroukhim R., Bronson R.T., Ryeom S., Hahn W.C., Loda M., Cichowski K. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappa B. Nat. Med. 2010, 16:286-294.
18. Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R., Paul J.E., Boyle M., Woolcock B.W., Kuchenbauer F., Yap D., Humphries R.K., Griffith O.L., Shah S., Zhu H., Kimbara M., Shashkin P., Charlot J.F., Tcherpakov M., Corbett R., Tam A., Varhol R., Smailus D., Moksa M., Zhao Y., Delaney A., Qian H., Birol I., Schein J., Moore R., Holt R., Horsman D.E., Connors J.M., Jones S., Aparicio S., Hirst M., Gascoyne R.D., Marra M.A. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 2010, 42:181-185.
19. Santarpia L., Ye L., Gagel R.F. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. J. Internal Med. 2009, 266:99-113.
20. Shin Y.J., Kim J.H. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. PLoS One 2012, 7:e30393.
21. Song L.B., Li J., Liao W.T., Feng Y., Yu C.P., Hu L.J., Kong Q.L., Xu L.H., Zhang X., Liu W.L., Li M.Z., Zhang L., Kang T.B., Fu L.W., Huang W.L., Xia Y.F., Tsao S.W., Li M., Band V., Band H., Shi Q.H., Zeng Y.X., Zeng M.S. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J. Clin. Invest. 2009, 119:3626-3636.
22. Sponziello M., Lavarone E., Pegolo E., Di Loreto C., Puppin C., Russo M.A., Bruno R., Filetti S., Durante C., Russo D., Di Cristofano A., Damante G. Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer. Endocrinology 2013, 154:3043-3053.
23. Tan J.Z., Yan Y., Wang X.X., Jiang Y., Xu H.E. EZH2: biology, disease, and structure-based drug discovery. Acta Pharmacol. Sin. 2014, 35:161-174.
24. Xu C., Hou Z., Zhan P., Zhao W., Chang C., Zou J., Hu H., Zhang Y., Yao X., Yu L., Yan J. EZH2 regulates cancer cell migration through repressing TIMP-3 in non-small cell lung cancer. Med. Oncol. 2013, 30:713.